Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer

Cediranib and chemo combo improves PFS for metastatic cervical cancer

Phase III trial results raise questions about the future of lung cancer vaccination

Little benefit for gefitinib-resistant lung cancer when continuing the drug with chemotherapy

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer

Adding cediranib to chemo improves PFS for metastatic cervical cancer

Rare cancers and the difficulties in making clinical decisions

New drug anamorelin shows improvement in appetite and body mass in non-small cell lung cancer with cancer anorexia-cachexia

Second-line afatinib significantly improves PFS in metastatic head and neck cancer

Optimising metastic renal cell carcinoma (mRCC): Treatment lessons from the real world: Introduction

Current treatment options in mRCC

Additional treatment options impact first-line treatment of mRCC: No